IMVT
Immunovant, Inc.
Immunovant, Inc. (IMVT) has 12 SEC Form 4 filings (26 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Jul 10, 2026.
The most active filer is Chief Legal Officer Van Tuyl Christopher with 3 filings. Insiders have net sold $4.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Eric Venker
- Employees:362
- HQ:New York City, NY, US
- IPO:2019-06-21
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$8.2B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Technology Officer | Sale | 3,487 | $138K | Jul 10 | SEC ↗ | |
| Chief Legal Officer | Sale | 1,206 | $48K | Jul 10 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,036 | $81K | Jul 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 3,092 | $119K | Jul 6 | SEC ↗ | |
Gloria MelanieFirst filing | Chief Operating Officer | Sale | 17,714 | $679K | Jun 26 | SEC ↗ |
Stout Jay SFirst filing | Chief Technology Officer | Sale | 40,000 | $1.5M | Jun 26 | SEC ↗ |
| Chief Legal Officer | Sale | 17,824 | $683K | Jun 26 | SEC ↗ | |
Girao TiagoFirst filing | Chief Financial Officer | Sale | 10,000 | $385K | Jun 26 | SEC ↗ |
| Director | Sale | 1,500 | $57K | Jun 26 | SEC ↗ | |
Van Tuyl ChristopherFirst filing | Chief Legal Officer | Sale | 2,634 | $93K | Jun 22 | SEC ↗ |
Pande AtulFirst filing | Director | Sale | 6,000 | $192K | May 21 | SEC ↗ |
Susman Robert GrahamFirst filing | Director | Sale | 2,502 | $68K | May 1 | SEC ↗ |
Related companies
Immunovant, Inc. is in the Healthcare sector.